Large Biopharma Company Engages LexaGene in Statement of Work to Expedite Technology Validation
20 oct. 2022 07h45 HE
|
LexaGene Holdings Inc
BEVERLY, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
LexaGene Receives Signed Quote from Large Biopharma Company to Purchase a MiQLab System
13 oct. 2022 07h45 HE
|
LexaGene Holdings Inc
BEVERLY, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
LexaGene Announces MiQLab® System Sale to Veterinary Hospital in California
01 sept. 2022 08h00 HE
|
LexaGene Holdings Inc
BEVERLY, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
LexaGene Verifies CDC Monkeypox Assay Works on MiQLab System and Readies Company Should an EUA be Declared
29 août 2022 08h00 HE
|
LexaGene Holdings Inc
BEVERLY, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
LexaGene’s MiQLab System Generates Leptospira Results in as Soon as 30 minutes using Isothermal Chemistry
24 août 2022 08h00 HE
|
LexaGene Holdings Inc
BEVERLY, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
University of Pennsylvania’s School of Veterinary Medicine to Evaluate New Gastrointestinal Panel Using LexaGene’s MiQLab System
17 août 2022 08h00 HE
|
LexaGene Holdings Inc
BEVERLY, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
LexaGene Reduces Time-to-Result by ~35%
10 août 2022 08h00 HE
|
LexaGene Holdings Inc
BEVERLY, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the...
LexaGene Announces Filing of Financial Statements, Revocation of MCTO & the Granting of Incentive Equity Awards to Employees
29 juil. 2022 07h58 HE
|
LexaGene Holdings Inc
BEVERLY, Mass., July 29, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the...
LexaGene Completes Multi-Center Validation Study Using MiQLab® System for Diagnosing Urinary Tract Infections
27 juil. 2022 07h58 HE
|
LexaGene Holdings Inc
BEVERLY, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the...
LexaGene Provides MCTO Update
12 juil. 2022 08h00 HE
|
LexaGene Holdings Inc
BEVERLY, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the...